Xiaofan Zhu, MD
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Emerging Leaders
#2630 pts
Current Leaders
#9229 pts
All-Time Leaders
#34630 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2022. 6 trials as lead/chair. How it works →
Trials led — by scientific impact
Chinese Children's Cancer Group T-cell Acute Lymphoblastic Leukemia -2025 Project
Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China
10
impact
Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed Low Risk Childhood B-cell Acute Lymphoblastic Leukemia
Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China
10
impact
Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed for Intermediate/High Risk Childhood B-cell ALL
Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China
6
impact
A Phase 3, Multicenter Trial for Pediatric Philadelphia Chromosome-positive B-Acute Lymphoblastic Leukemia -2025 Project
Phase 3RecruitingInstitute of Hematology & Blood Diseases Hospital, China
4
impact
Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia
Early Ph 1UnknownInstitute of Hematology & Blood Diseases Hospital, China
0
impact
Study for Safety and Efficacy Evaluation of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (R/R Ph + ALL）
Phase 1UnknownInstitute of Hematology & Blood Diseases Hospital, China
0
impact